Top

Published in:

01-01-2017 | Original Article

Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer

Authors: Kazuhiko Sato, Yoshio Mizuno, Hiromi Fuchikami, Masahiro Kato, Takahiro Shimo, Jun Kubota, Naoko Takeda, Yuko Inoue, Hiroshi Seto, Tomohiko Okawa

Published in: Breast Cancer | Issue 1/2017

Abstract

Background

Partial breast irradiation (PBI) is an alternative to whole breast irradiation (WBI) for breast-conserving therapy (BCT). A randomised phase 3 trial demonstrated that PBI using multicatheter brachytherapy had an equivalent rate of local recurrence, disease-free survival, and overall survival as compared to WBI. However, limited data are available on PBI efficacy for young patients with breast cancer.

Methods

We evaluated consecutive patients with Tis-2 (≤ 3 cm) N0-1 breast cancer who underwent BCT. For PBI, patients received radiotherapy using multicatheter brachytherapy in an accelerated manner with a dose of 32 Gy in eight fractions over 5–6 days. For WBI, patients received an external beam radiation therapy that was applied to the entire breast with a total dose of 50 Gy in fractions of 2 Gy for 5 weeks. Two hundred seventy-four patients with 278 lesions received PBI; 190 patients with 193 lesions received WBI.

Results

Patients aged <50 years including 98 women with 99 lesions receiving PBI and 85 women with 85 lesions receiving WBI were selected. Ipsilateral breast tumor recurrence rate was 3.0 and 2.4 % by PBI and WBI, respectively (P = 0.99). There was no significant difference in 4-year probability of disease-free survival (97.6 and 91.4 % for PBI and WBI, respectively; P = 0.87).

Conclusions

This is the first report of PBI efficacy in young patients in Asia. Although it is a nonrandomized retrospective chart review of a small cohort of patients with a relatively short follow-up period, PBI may be a better option than WBI following BCS in some young patients with breast cancer.

Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11:101–15. doi:10.7497/j.issn.2095-3941.2014.02.005.PubMedPubMedCentral

Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22:235–44. doi:10.1007/s12282-015-0599-6.CrossRefPubMed

Kim Z, Min SY, Yoon CS, Jung KW, Ko BS, Kang E, et al. The basic facts of Korean Breast Cancer in 2012: results from a Nationwide Survey and Breast Cancer Registry Database. J Breast Cancer. 2015;18:103–11. doi:10.4048/jbc.2015.18.2.103.CrossRefPubMedPubMedCentral

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMed

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMed

Fisher CM, Rabinovitch R. Frontiers in radiotherapy for early-stage invasive breast cancer. J Clin Oncol. 2014;32:2894–901. doi:10.1200/JCO.2014.55.1184.CrossRefPubMedPubMedCentral

Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors. Cancer. 2012;118:2004–13. doi:10.1002/cncr.26505.CrossRefPubMed

Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004–2009. Breast Cancer. 2012;19:1–3. doi:10.1007/s12282-011-0308-z.CrossRefPubMed

Skandarajah AR, Mann GB. Do all patients require radiotherapy after breast-conserving surgery? Cancers. 2010;2:740–51. doi:10.3390/cancers2020740.CrossRefPubMedPubMedCentral

10.

Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7. doi:10.1200/JCO.2012.45.2615.CrossRefPubMedPubMedCentral

11.

Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266–73. doi:10.1016/S1470-2045(14)71221-5.CrossRefPubMed

12.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefPubMed

13.

Pan IW, Smith BD, Shih YC. Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst. 2014;106:340. doi:10.1093/jnci/djt340.CrossRef

14.

Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, et al. Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg. 2015;150:778–86. doi:10.1001/jamasurg.2015.1102.CrossRefPubMedPubMedCentral

15.

Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2015;S0140–6736(15):00471–7. doi:10.1016/S0140-6736(15)00471-7.

16.

Sato K, Mizuno Y, Kato M, Shimo T, Kubota J, Takeda N, et al. Intraoperative open-cavity implant for accelerated partial breast irradiation using high-dose rate multicatheter brachytherapy in Japanese breast cancer patients: a single-institution registry study. J Cancer Ther. 2012;3:822–30. doi:10.4236/jct.2012.325104.CrossRef

17.

Recht A, Silver B, Schnitt S, Connolly J, Hellman S, Harris JR. Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;11:1271–6. doi:10.1016/0360-3016(85)90241-X.CrossRefPubMed

18.

Saika K, Sobue T. Epidemiology of breast cancer in Japan and the USA. JMAJ. 2009;52:39–44.

19.

American Society of Breast surgeons: Consensus Statements. Accelerated partial breast irradiation. In: American Society of Breast surgeons Web site. 2015. https://www.breastsurgeons.org/statements/PDF_Statements/APBI.pdf. Accessed 1 Sep 2015.

20.

Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2013;12:267–77. doi:10.1016/j.brachy.2013.02.001.CrossRefPubMed

21.

Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001. doi:10.1016/j.ijrobp.2009.02.031.CrossRefPubMed

22.

Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264–73. doi:10.1016/j.radonc.2010.01.014.CrossRefPubMed

23.

Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6. doi:10.1200/JCO.2014.55.1572.CrossRefPubMed

24.

King TA. Selecting local therapy in the young breast cancer patient. J Surg Oncol. 2011;103:330–6. doi:10.1002/jso.21697.CrossRefPubMed

25.

Stull TS, Catherine Goodwin M, Chernick MR, Carella RJ, Frazier TG, et al. A single-institution review of accelerated partial breast irradiation in patients considered “cautionary” by the American Society for Radiation Oncology. Ann Surg Oncol. 2012;19:553–9. doi:10.1245/s10434-011-1941-7.CrossRefPubMed

26.

Sato K, Mizuno Y, Fuchikami H, Kato M, Shimo T, Kubota J, et al. Single-institution comparison of accelerated partial breast irradiation and whole breast irradiation in breast cancer patients with unfavorable parameters by the American Society for Radiation Oncology guidelines. J Tumor. 2014;2:129–33.

27.

Sedlmayer F, Zehentmayr F, Fastner G. Partial breast re-irradiation for local recurrence of breast carcinoma: benefit and long term side effects. Breast. 2013;22(Suppl 2):S141–6. doi:10.1016/j.breast.2013.07.026.CrossRefPubMed

28.

Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98. doi:10.1056/NEJMoa1209825.CrossRefPubMed

29.

Sato K, Mizuno Y, Fuchikami H, Kato M, Shimo T, Kubota J, et al. Comparison of radiation dose to the left anterior descending artery by whole and partial breast irradiation in breast cancer patients. J Contemp Brachytherapy. 2015;7:23–8. doi:10.5114/jcb.2014.47891.CrossRefPubMedPubMedCentral

30.

Amin M, Gabram S, Bumpers H, Landry J, Jani AB, Diaz R, et al. Feasibility of accelerated partial breast irradiation in a large inner-city public hospital. Ann Surg Oncol. 2012;19:4094–8. doi:10.1245/s10434-012-2444-x.CrossRefPubMed

31.

Pasko J, Schray M, Lee M, Johnson N. Experience with partial breast irradiation for treatment of breast cancer at a community-based cancer center. Am J Surg. 2014;207:682–5. doi:10.1016/j.amjsurg.2013.12.025.CrossRefPubMed

32.

Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–77. doi:10.1016/S1470-2045(13)70497-2.CrossRefPubMed

33.

Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13. doi:10.1016/S0140-6736(13)61950-9.CrossRefPubMed

34.

Polgár C, Fodor J, Major T, Sulyok Z, Kásler M. Breast-conserving therapy with partial or whole breast irradiation: 10-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202. doi:10.1016/j.radonc.2013.05.008.CrossRefPubMed

35.

Kamrava M, Kuske RR, Anderson B, Chen P, Hayes J, Quiet C, et al. Outcomes of breast cancer patients treated with accelerated partial breast irradiation via multicatheter interstitial brachytherapy: the pooled registry of multicatheter interstitial sites (PROMIS) experience. Ann Surg Oncol. 2015;22:404–11. doi:10.1245/s10434-015-4563-7. CrossRef

36.

Chen PY, Shah C, Wilkinson JB, et al. Efficacy of young patients treated with accelerated partial breast irradiation for early-stage breast cancer. Radiother Oncol. 2012;103(Suppl 2):S36–7. doi:10.1016/S0167-8140(12)72057.CrossRef

Title: Impact of young age on local control after partial breast irradiation in Japanese patients with early stage breast cancer
Authors: Kazuhiko Sato
Yoshio Mizuno
Hiromi Fuchikami
Masahiro Kato
Takahiro Shimo
Jun Kubota
Naoko Takeda
Yuko Inoue
Hiroshi Seto
Tomohiko Okawa
Publication date: 01-01-2017
Publisher: Springer Japan
Published in: Breast Cancer / Issue 1/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-016-0669-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer

A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women

Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer

The roles of 18F-FDG-PET/CT and US-guided FNAC in assessment of axillary nodal metastases in breast cancer patients

The benefit of deep inspiration breath hold: evaluating cardiac radiation exposure in patients after mastectomy and after breast-conserving surgery

Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer